Contact

Category: Human Treatments

Human Treatments summarizes the human clinical pharmacology, World Health Organization (WHO) essential medicine guidelines, and validated medical treatments for human parasitic infections.

Foundational Pillars
Pharmacological Framework
Clinical Directory
Frequently Asked Questions

Foundational Clinical Pillars

Core Reference

The Longevity of Ivermectin: A Detailed Chronicle of Clinical Use Across Five Decades

Clinical evidence review and oral posology protocols for human Sarcoptes scabiei eradication.

Clinical Benchmark

How Long Has Ivermectin Been Around? A 50-Year History from 1974 to the Present

Broad-spectrum pharmacological efficacy across filarial, intestinal, and ectoparasitic human pathogens.

Safety Standard

Where Did Ivermectin Come From? The Discovery of Streptomyces avermitilis and Satoshi Ōmura

Analysis of regulated pharmaceutical cleansing protocols, dosage limits, and patient monitoring.

WHO Essential Anthelmintics, Human Pharmacology & Clinical Guidelines

In human medicine, ivermectin is recognized on the World Health Organization Model List of Essential Medicines for its transformative role in combating neglected tropical diseases. The primary established indications include Onchocerciasis (River Blindness caused by Onchocerca volvulus), Strongyloidiasis (Strongyloides stercoralis), and Lymphatic Filariasis.

For human ectoparasitic infestations, oral ivermectin dosed at 200 mcg/kg is a first-line treatment for crusted (Norwegian) scabies and refractory pediculosis (head lice). Because ivermectin does not penetrate the protective chitin of parasite ova, a second dose administered 7 to 14 days later is clinically necessary to eradicate newly hatched larvae before they achieve reproductive maturity.

Human Clinical IndicationStandard Human RegimenClinical Efficacy & Outcome
Onchocerciasis (River Blindness)150 mcg/kg single oral doseSuppresses skin microfilariae for 6-12 months; annual treatment
Strongyloidiasis (Threadworm)200 mcg/kg daily for 1-2 daysAchieves 85-95% parasitological cure rates in immunocompetent hosts
Classical Scabies (Sarcoptes)200 mcg/kg repeated in 7-14 daysEradicates mites; second dose kills newly emerged nymphs
Crusted (Norwegian) Scabies200 mcg/kg on days 1, 2, 8, 9, 15Combined with topical permethrin and keratolytic therapy

Human pharmaceutical tablets (Stromectol, 3 mg) are formulated under stringent cGMP standards to ensure precise bioavailability and metabolic clearance. Human clinical guidelines explicitly warn against consuming veterinary or livestock-grade preparations, which lack human safety excipients and carry immense risks of formulation-induced toxicity.

Topic Directory & Methodologies

Human Clinical Posology & Tropical Medicine

Scabies, Lice & Ectoparasitic Dermatoses

Advanced Formulations & Protocols

Frequently Asked Clinical Questions

Can humans take veterinary ivermectin?

No. Veterinary products are formulated for animal body weights, contain unpurified industrial excipients, and carry high risk of severe overdose, organ toxicity, and death in humans.

Why is a second dose necessary when treating scabies with ivermectin?

Ivermectin kills living mites but does not destroy mite eggs. The second dose given 7 to 14 days later eliminates newly hatched nymphs before they can reproduce.

What are the most common side effects of human ivermectin treatment?

When treating filarial infections, side effects usually stem from the immune response to dying microfilariae (Mazzotti reaction), including fever, rash, itching, and joint pain.

Notice & Clinical Safe Harbor: This educational reference is maintained by the Veterinary Parasitology & Pharmacology Standards Desk for academic, informational, and clinical research purposes. Data models published veterinary pharmacology literature, statutory veterinary monographs, and established anthelmintic posology standards. This portal does not provide certified individual veterinary medical diagnosis, prescription services, or personalized treatment regimens. For clinical diagnoses, suspected parasitic toxicosis, and individualized dosing protocols, always consult an actively licensed veterinary practitioner in your jurisdiction.

AI Editorial Policy